APA (7th ed.) Citation

M, P., SL, C., A, T., R, G., L, G., A, S., . . . A, C. (2025). Long-term trajectories of hepatic and metabolic biomarkers after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral therapy-experienced people with HIV with and without hepatic coinfection: Data from the ICONA cohort. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 161, 108081. https://doi.org/10.1016/j.ijid.2025.108081

Chicago Style (17th ed.) Citation

M, Poliseno, et al. "Long-term Trajectories of Hepatic and Metabolic Biomarkers After Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Antiretroviral Therapy-experienced People with HIV with and Without Hepatic Coinfection: Data from the ICONA Cohort." International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases 161 (2025): 108081. https://doi.org/10.1016/j.ijid.2025.108081.

MLA (9th ed.) Citation

M, Poliseno, et al. "Long-term Trajectories of Hepatic and Metabolic Biomarkers After Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Antiretroviral Therapy-experienced People with HIV with and Without Hepatic Coinfection: Data from the ICONA Cohort." International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases, vol. 161, 2025, p. 108081, https://doi.org/10.1016/j.ijid.2025.108081.